Accordingly, publicly accessible transcriptome analyses on roughly 300 non-randomized patients affected by AML (considering all variants) highlight that upregulation/de novo transcription of a least five distinct proteoglycans, including Agrin, Biglycan, Perlecan, Glypican-2, Glypican-5 and Podocan-like protein-1, significantly impacts on overall survival of the patients over a 9/10-year follow-up period (Fig. 6). Here, GPC2 is linked to acute myeloid leukemia.